Exhibit 99.1 Pursuant to General Instruction number 5(b)(v) to Form 3, the following additional reporting persons are covered by this joint filing: Name: Foresite Capital Fund II, L.P. James B. Tananbaum Address: Foresite Capital 101 California Street Suite 4100 San Francisco, CA 94111 Designated Filer: Foresite Capital Management II, LLC Issuer and Ticker Symbol: Aimmune Therapeutics, Inc. (AIMT) Date of Event Requiring Statement: August 5, 2015 Each of the following is a Joint Filer with Foresite Capital Management II, LLC ("FCM II") and may be deemed to share indirect beneficial ownership in the securities set forth on the attached Form 3: FCM II is the general partner of Foresite Capital Fund II, L.P. ("FCF II"). As such, FCM II possesses sole voting and investment control over the shares owned by FCF II, and may be deemed to have indirect beneficial ownership of the securities held by FCF II, however, owns no shares of the Issuer directly. Mr. Tananbaum is the managing member of FCM II and in his capacity as such, may be deemed to exercise shared voting, investment and dispositive power over the shares held by FCF II. Each Reporting Person disclaims beneficial ownership of the shares held by FCF II except to the extent of his or its proportionate pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, or otherwise, any of the Reporting Persons are the beneficial owners of all of the equity securities covered by this statement. Each of the Reporting Persons listed above hereby designates FCM II as its designated filer of Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder. FORESITE CAPITAL MANAGEMENT II, LLC By: /s/ Dennis D. Ryan -------------------------------- Dennis D. Ryan Chief Financial Officer FORESITE CAPITAL FUND II, L.P By: Foresite Capital Management II, LLC Its General Partner By: /s/ Dennis D. Ryan -------------------------------- Dennis D. Ryan Chief Financial Officer /s/ James B. Tananbaum ---------------------------------------- James B. Tananbaum
- Company Dashboard
- Filings
- Holdings
-
3 Filing
Foresite Capital Management II Form 3Aimmune Therapeutics / James B. Tananbaum ownership change
Filed: 5 Aug 15, 12:00am